Nkarta therapeutics ceo, paul hastings, named bio chair for 2021-2022 term

South san francisco, calif., june 14, 2021 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced that chief executive officer paul hastings has been elected as the chair of the biotechnology innovation organization (bio) board of directors for the 2021-2022 term.
NKTX Ratings Summary
NKTX Quant Ranking